RGNX
NASDAQ · Biotechnology
Regenxbio Inc
$9.84
+0.62 (+6.72%)
Open$9.35
Previous Close$9.22
Day High$10.08
Day Low$9.30
52W High$16.19
52W Low$6.89
Volume—
Avg Volume776.0K
Market Cap543.01M
P/E Ratio—
EPS$-3.75
SectorBiotechnology
Analyst Ratings
Strong Buy
19 analysts
Price Target
+87.8% upside
Current
$9.84
$9.84
Target
$18.48
$18.48
$13.35
$18.48 avg
$24.09
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 182.37M | 158.89M | 81.92M |
| Net Income | -207,454,257 | -162,666,693 | 13.19M |
| Profit Margin | -113.8% | -108.1% | 16.1% |
| EBITDA | -155,669,331 | -128,842,885 | 28.49M |
| Free Cash Flow | — | — | 20.59M |
| Rev Growth | +14.8% | +14.8% | +8.8% |
| Debt/Equity | 1.82 | 1.82 | 0.43 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |